Literature DB >> 3441909

Intravascular release of platelet activating factor in children with sepsis.

F Bussolino, M G Porcellini, L Varese, A Bosia.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3441909     DOI： 10.1016/0049-3848(87)90396-3

Source DB:  PubMed          Journal:  Thromb Res        ISSN： 0049-3848            Impact factor:   3.944


× No keyword cloud information.
  7 in total

1.  Effect of a selective PAF antagonist SM-10661 ((+/-)-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one HCl) on experimental disseminated intravascular coagulation (DIC).

Authors:  N Imanishi; Y Komuro; S Morooka
Journal:  Lipids       Date:  1991-12       Impact factor: 1.880

2.  A double-blind placebo-controlled study of an infusion of lexipafant (Platelet-activating factor receptor antagonist) in patients with severe sepsis.

Authors:  Y Suputtamongkol; S Intaranongpai; M D Smith; B Angus; W Chaowagul; C Permpikul; J A Simpson; A Leelarasamee; L Curtis; N J White
Journal:  Antimicrob Agents Chemother       Date:  2000-03       Impact factor: 5.191

3.  Intravascular release of a platelet-activating factor-like lipid (PAF-LL) induced by cigarette smoking.

Authors:  T Imaizumi
Journal:  Lipids       Date:  1991-12       Impact factor: 1.880

4.  Endotoxin-resistant mice are protected from PAF-induced bowel injury and death. Role of TNF, complement activation, and endogenous PAF production.

Authors:  X Sun; M S Caplan; Y Liu; W Hsueh
Journal:  Dig Dis Sci       Date:  1995-03       Impact factor: 3.199

5.  Efficacy and Safety of the Platelet-Activating Factor Receptor Antagonist BN 52021 (Ginkgolide B) in Patients with Severe Sepsis : A Randomised, Double-Blind, Placebo-Controlled, Multicentre Trial.

Authors:  D M Albrecht; K van Ackern; H-J Bender; H Hof; W Kox; N Victor; P Funk; M Kieser; S Köhler; D Krausch; I Marzi; T Menges; H Schmidt
Journal:  Clin Drug Investig       Date:  2004       Impact factor: 2.859

Review 6.  Involvement of platelet-activating factor (PAF) in septic shock and priming as indicated by the effect of hetrazepinoic PAF antagonists.

Authors:  H O Heuer
Journal:  Lipids       Date:  1991-12       Impact factor: 1.880

7.  Platelet-activating factor type activity in plasma from patients with septicemia and other diseases.

Authors:  H O Heuer; H Darius; H F Lohmann; J Meyer; M Schierenberg; N Treese
Journal:  Lipids       Date:  1991-12       Impact factor: 1.880
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.